What exactly did Cowen change in the NVO analyst rating on Feb 3, 2026?

Cowen did not change its stance. On **Feb 03, 2026** Cowen **maintained** a **Buy** rating on Novo Nordisk A/S (NVO). The note did not include a new price target and listed price data as N/A.

How should investors interpret a maintained Buy for NVO?

A maintained Buy means the analyst keeps positive conviction. It signals confidence in future performance but not a new catalyst. Investors should watch earnings, GLP-1 market moves, and consensus price targets.

Did Cowen set a new NVO price target with the maintained Buy?

No. The Cowen note published via StreetInsider did not list a new **NVO price target**. The report reiterated the Buy without disclosing a fresh numeric target.

How does Cowen’s note fit with broader analyst coverage of NVO?

Cowen’s maintained Buy aligns with a broader Buy-leaning consensus. Investing.com lists about 11 analysts on Novo Nordisk with a plurality recommending Buy, giving context to Cowen’s stance.

Analyst Ratings

Cowen Maintains Buy on Novo Nordisk A/S (NVO) Feb 2026

ByDanny Kontos February 4, 2026

Cowen & Co. maintained its Buy rating on Novo Nordisk A/S (NVO) on February 3, 2026. The firm reiterated the buy stance without a new public price target in the released note. The NVO analyst rating action came as the stock showed a -13.25% move since the prior note, a differential of $-7.68. This brief update explains the rating, context, and what it means for investors.